Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainstorm Cell Therapeutics

NEW YORK and SOMERSET, N.J., Dec. 7, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: CTLT), a global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that the technology transfer for NurOwn® manufacturing at Catalent's facility has been finalized.

BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Catalent (CTLT) Down 6.4% Since Last Earnings Report: Can It Rebound?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Catalent (CTLT) is a Top Growth Stock for the Long-Term

Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2021 Results - Earnings Call Transcript

Catalent's (CTLT) robust performance across most of its segments drives its first-quarter fiscal 2022 top line.

Catalent (CTLT) Q1 Earnings Top Estimates, FY22 View Up

Catalent (CTLT) delivered earnings and revenue surprises of 7.58% and 1.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Q1 Earnings and Revenues Surpass Estimates

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the first quarter of fiscal 2022, which ended September 30, 2021. “Catalent's strong start to fiscal 2022 was driven by robust growth in our Biologics segment and improving dynamics in both our Softgel and Oral Technologie

Catalent, Inc. Reports First Quarter Fiscal 2022 Results

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.

Catalent (CTLT) to Report Q1 Earnings: What's in Store?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2022 ended September 30, 2021, before the market open on Tuesday, November 2, 2021. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET

Catalent, Inc. Announces First Quarter Fiscal Year 2022 Earnings Conference Webcast

Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.

Catalent (CTLT) Expands Presence in Japan Via New Facility

Catalent has enjoyed significant revenue growth over the pandemic, with its Biologic segment showing a massive 89% net revenue increase over the past 12 months.

Catalent: Biologic-Driven Organic Growth

Anthem

CVS Health

Medtronic

Pfizer

Teladoc

UnitedHealth Group

Healthcare stocks could take over from energy stocks as top dog during this defensive cycle as yields move higher and tech stocks lose value. The post 7 Healthcare Stocks to Add to Your Portfolio appeared first on InvestorPlace.

7 Healthcare Stocks to Add to Your Portfolio

Baxter

Boston Scientific

Hill-Rom Hlds

Intersect ENT

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

Why Is Catalent (CTLT) Up 2.1% Since Last Earnings Report?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $650 million in aggregate principal amount of 3.500% senior unsecured notes due 2

Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $450 million in aggregate principal amount of senior unsecured notes due 2030

Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that members of its executive leadership team will virtually present at the Morgan Stanley 19th Annual Global Healthcare Conference at 1:15 a.m. ET on September 9, 2021. A live webcast of the presentation will be accessible at http://investor.c

Catalent, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

(Catalent:CTLT) stock rose by 0.1% after the company reported their Q4 earnings results on Monday, August 30, 2021 at 10:50 PM. Here's what investors need to know about the announcement.

Recap: Catalent Q4 Earnings

Catalent has been doing extremely well in recent years on the back of organic growth, bolt-on deals, and the pandemic. I like the track record of the business and while the business has been doing well, expectations have risen quite a bit here.

Catalent - Missing The Catalyst After The Pandemic

Catalent, Inc.'s (CTLT) CEO John Chiminski on Q4 2021 Results - Earnings Call Transcript

Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.

Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise

Catalent (CTLT) delivered earnings and revenue surprises of 11.54% and 5.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Q4 Earnings and Revenues Surpass Estimates

Catalent Inc (NYSE: CTLT) has reported Q4 sales of $1.19 billion, +25% Y/Y as reported, or 22% in constant currency, edging out analysts' average expectation of $1.14 billion. Adjusted EPS of $1.16 surpassed the consensus of $1.03.

Catalent Makes Strategic Move For Consumer Health Business With Bettera Deal

Catalent Inc. CTLT, -0.35% said Monday it has reached an agreement to acquire Bettera Holdings LLC, a maker of gummy, soft chew and lozenges as nutritional supplements, from Highlander Partners LP for $1 billion in cash. Bettera has "broad and difficult-to-replicate expertise" in developing and producing products for nutraceutical, functional, and botanical ingredients, and has four production facilities in the U.S., Catalent said in a statement.

Catalent to acquire gummy maker Bettera from Highlander Partners for $1 billion in cash

DALLAS, Aug. 30, 2021 /PRNewswire/ -- Highlander Partners ("Highlander") today announced that it has entered into a definitive agreement under which Catalent, Inc. (NYSE: CTLT) will acquire Highlander's portfolio company, Bettera Holdings, LLC, the parent company of Bettera Brands ("Bettera"), for $1 billion.  Bettera is a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market.

News for Catalent Stock (CTLT)